Search Results | Clinical Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Keith L. Knutson, Matthew S. Block, Nadine Norton, Courtney L. Erskine, Timothy J. Hobday, Allan B. Dietz, Douglas Padley, Michael P. Gustafson, Danell Puglisi-Knutson, Toni Kay Mangskau, Saranya Chumsri, Amylou C. Dueck, Lavakumar Karyampudi, Glynn Wilson, Amy C. Degnim

Clin Cancer Res (2020) 26 (5): 1045–1053.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-2123

Published: 02 March 2020

View article

Journal Articles

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Saranya Chumsri, Daniel J. Serie, Zhuo Li, Katherine L. Pogue-Geile, Aixa E. Soyano-Muller, Afshin Mashadi-Hossein, Sarah Warren, Yanyan Lou, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E. Aubrey Thompson

Clin Cancer Res (2019) 25 (14): 4422–4430.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-2206

Published: 15 July 2019

View article

Includes: Supplementary data

Journal Articles

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

Kimberly R. Kalli, Matthew S. Block, Pashtoon M. Kasi, Courtney L. Erskine, Timothy J. Hobday, Allan Dietz, Douglas Padley, Michael P. Gustafson, Barath Shreeder, Danell Puglisi-Knutson, Dan W. Visscher, Toni K. Mangskau, Glynn Wilson, Keith L. Knutson

Clin Cancer Res (2018) 24 (13): 3014–3025.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2499

Published: 01 July 2018

View article

Includes: Supplementary data

Journal Articles

Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development

Amy C. Degnim, Tanya L. Hoskin, Muhammad Arshad, Marlene H. Frost, Stacey J. Winham, Rushin A. Brahmbhatt, Alvaro Pena, Jodi M. Carter, Melody L. Stallings-Mann, Linda M. Murphy, Erin E. Miller, Lori A. Denison, Celine M. Vachon, Keith L. Knutson, Derek C. Radisky, Daniel W. Visscher

Clin Cancer Res (2017) 23 (14): 3945–3952.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2026

Published: 13 July 2017

View article

Includes: Supplementary data

Journal Articles

Abstract POSTER-THER-1418: PD-1 mediated paralysis of ovarian cancer infiltrating dendritic cells

Lavakumar Karyampudi, James Krempski, Purushottam Lamichhane, Kimberly R. Kalli, Marshall D. Behrens, Doris M. Vargas, Lynn C Hartmann, Karen E Hedin, Ellen L. Goode, Keith L. Knutson

Clin Cancer Res (2015) 21 (16_Supplement): POSTER-THER-1418.

DOI: https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-THER-1418

Published: 15 August 2015

View article

Journal Articles

Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

Kimberly R. Kalli, Courtney L. Erskine, James W. Krempski, Linda M. Benson, Vera J. Suman, Douglas J. Padley, Allan B. Dietz, Timothy J. Hobday, Amy C. Degnim, Lynn C. Hartmann, Matthew S. Block, Keith L. Knutson

Clin Cancer Res (2013) 19 (19_Supplement): A82.

DOI: https://doi.org/10.1158/1078-0432.OVCA13-A82

Published: 13 May 2014

View article

Journal Articles

A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu_88-102

Lavakumar Karyampudi, Courtney Formicola, Courtney L. Erskine, Matthew J. Maurer, James N. Ingle, Christopher J. Krco, Peter J. Wettstein, Kimberly R. Kalli, John D. Fikes, Melanie Beebe, Lynn C. Hartmann, Mary L. Disis, Soldano Ferrone, Glenn Ishioka, Keith L. Knutson

Clin Cancer Res (2010) 16 (3): 825–834.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-2781

Published: 01 February 2010

View article

Journal Articles

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

Clare Taylor, Dawn Hershman, Nina Shah, Nicole Suciu-Foca, Dan P. Petrylak, Robert Taub, Linda Vahdat, Bin Cheng, Mark Pegram, Keith L. Knutson, Raphael Clynes

Clin Cancer Res (2007) 13 (17): 5133–5143.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-0507

Published: 04 September 2007

View article

Journal Articles

Tumor-Infiltrating Foxp3⁻CD4⁺CD25⁺ T Cells Predict Poor Survival in Renal Cell Carcinoma

Sameer A. Siddiqui, Xavier Frigola, Sandra Bonne-Annee, Maria Mercader, Susan M. Kuntz, Amy E. Krambeck, Shomik Sengupta, Haidong Dong, John C. Cheville, Christine M. Lohse, Christopher J. Krco, W. Scott Webster, Bradley C. Leibovich, Michael L. Blute, Keith L. Knutson, Eugene D. Kwon

Clin Cancer Res (2007) 13 (7): 2075–2081.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-2139

Published: 02 April 2007

View article

Journal Articles

Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming

Yushe Dang, Keith L. Knutson, Vivian Goodell, Corazon dela Rosa, Lupe G. Salazar, Doreen Higgins, Jennifer Childs, Mary L. Disis

Clin Cancer Res (2007) 13 (6): 1883–1891.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-2083

Published: 15 March 2007

View article

Journal Articles

Immunization of Cancer Patients with HER-2/ neu -Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles

Lupe G. Salazar, John Fikes, Scott Southwood, Glenn Ishioka, Keith L. Knutson, Theodore A. Gooley, Kathy Schiffman, Mary L. Disis

Clin Cancer Res (2003) 9 (15): 5559–5565.

Published: 03 December 2003

View article

Journal Articles

Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

Keith L. Knutson, Kathy Schiffman, Martin A. Cheever, Mary L. Disis

Clin Cancer Res (2002) 8 (5): 1014–1018.

Published: 01 May 2002

View article

Journal Articles

Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization

Mary L. Disis, Kathy Schiffman, Theodore A. Gooley, Douglas G. McNeel, Kristine Rinn, Keith L. Knutson

Clin Cancer Res (2000) 6 (4): 1347–1350.

Published: 01 April 2000

View article

NARROW

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development

Abstract POSTER-THER-1418: PD-1 mediated paralysis of ovarian cancer infiltrating dendritic cells

Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu_88-102

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

Tumor-Infiltrating Foxp3⁻CD4⁺CD25⁺ T Cells Predict Poor Survival in Renal Cell Carcinoma

Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming

Immunization of Cancer Patients with HER-2/ neu -Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles

Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only